Article information
Full text is only aviable in PDF
REFERENCES
[1]
ATS.
Proceedings of the ATS Workshop on Refractory Asthma.
Am J Respir Crit Care Med., 162 (2000), pp. 2341-2351
[2]
J Serra-Batlles, V Plaza, E Morejón, A Comella, J Brugues.
Cost of asthma according to the degree of severity.
Eur Respir J., 12 (1998), pp. 1322-1326
[3]
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. 2002.
[4]
DW Cockcroft, VA Swystun.
Asthma control versus asthma seve rity.
J Allergy Clin Immunol., 98 (1996), pp. 1016-1018
[5]
US Department of Health and Human Services.
International consensus report of diagnosis and treatment of asthma, National Heart, Lung and Blood Institute, (1992),
[6]
A López Viña.
Actitudes para fomentar el cumplimiento terapéutico en el asma.
Arch Bronconeumol., 41 (2005), pp. 334-340
[7]
AE Tattersfield, DS Postma, PJ Barnes, K Svensson, CA Bauer, PM O'Byrne, et al.
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.
Am J Respir Crit Care Med., 160 (1999), pp. 594-599
[8]
AJ Woolcock, K Yan, CM Salome.
Effect of therapy on bronchial hyperresponsiveness in the long-term management of asthma.
Clin Allergy, 18 (1988), pp. 165-176
[9]
MR Sears, DR Taylor, CG Print, DC Lake, Q Li, EM Flannery, et al.
Regular inhaled beta-agonist treatment in bronchial asthma.
Lancet, 336 (1990), pp. 1391-1396
[10]
PS Thomas, DM Geddes, PJ Barnes.
Pseudo-steroid resistant asthma.
Thorax, 54 (1999), pp. 352-356
[12]
DS Robinson, DA Campbell, SR Durham, J Pfeffer, PJ Barnes, KF Chung.
Systematic assessment of difficult-to-treat asthma.
Eur Respir J., 22 (2003), pp. 478-483
[13]
LG Heaney, E Conway, C Kelly, BT Johnston, C English, M Steven son, et al.
Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol.
Thorax, 58 (2003), pp. 561-566
[14]
The ENFUMOSA study group: The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma.
Eur Respir J., 22 (2003), pp. 470-477
[15]
IM Adcock, CR Brown, H Shirasaki, PJ Barnes.
Effects of dexamethasone on cytokine and phorbol ester stimulated c-Fos and c-Jun DNA binding and gene expression in human lung.
Eur Respir J., 7 (1994), pp. 2117-2123
[16]
AT Brinke, AH Zwinderman, PJ Sterk, F Rabe, EH Bel.
“Refractory” eosinophilic airway inflammation in severe asthma.
Am J Respir Crit Care Med., 170 (2004), pp. 601-605
[17]
IM Adcock, DA Stevens, PJ Barnes.
Interactions of glucocorticoids and beta 2-agonists.
Eur Respir J., 9 (1996), pp. 160-168
[18]
P Lange, J Parner, J Vestbo, Schnohr, JA Jensen.
A 15-year follow up study of ventilatory function in adults with asthma.
N Engl J Med., 339 (1998), pp. 310-312
[19]
F Paganin, E Seneterre, P Chanez, JP Daures, JM Cruel, FB Michel, et al.
Computed tomography of the lungs in asthma: influence of disease severity and etiology.
Am J Respir Crit Care Med., 153 (1996), pp. 110-114
[20]
GE Silva, DL Sherrill, S Guerra, RA Barbee.
Asthma as a risk factor for COPD in a longitudinal study.
Chest, 126 (2004), pp. 59-65
[21]
N Jarjour, K McGill, WW Busse, E Gelfand.
Alternative anti-inflammatory and immunomodulatory therapy.
Lung biology in health and disease. Vol. 86. Severe asthma: pathogenesis and clinical management, pp. 333-339
[23]
S Holgate, R Djukanovic, T Casale, J Bousquet.
Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Clin Exp Allergy, 35 (2005), pp. 408-416
[24]
JM Vonk, DS Postma, HN Boezen, MH Grol, JP Schouten, GH Koeter, et al.
Childhood factors associated with asthma remission after 30 year follow up.
Thorax, 59 (2004), pp. 925-929
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
